Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Heron Therapeutics, Inc. (NASDAQ:HRTX)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.37 and traded as high as $1.45. Heron Therapeutics shares last traded at $1.44, with a volume of 706,371 shares trading hands.

Analyst Upgrades and Downgrades

HRTX has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a research report on Friday, January 9th. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Trading Up 1.4%

The company has a current ratio of 2.56, a quick ratio of 1.78 and a debt-to-equity ratio of 19.89. The company has a fifty day moving average price of $1.30 and a two-hundred day moving average price of $1.37. The firm has a market capitalization of $264.04 million, a price-to-earnings ratio of -16.00 and a beta of 1.28.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $38.21 million during the quarter, compared to analysts’ expectations of $39.03 million. As a group, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Heron Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Clearline Capital LP grew its stake in shares of Heron Therapeutics by 1,033.1% in the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock valued at $12,238,000 after buying an additional 8,855,361 shares during the period. Baker BROS. Advisors LP acquired a new position in Heron Therapeutics in the third quarter valued at approximately $5,357,000. Citigroup Inc. grew its position in Heron Therapeutics by 4,666.9% in the third quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock worth $3,120,000 after acquiring an additional 2,424,576 shares during the period. Rubric Capital Management LP grew its position in Heron Therapeutics by 8.9% in the third quarter. Rubric Capital Management LP now owns 29,100,728 shares of the biotechnology company’s stock worth $36,667,000 after acquiring an additional 2,387,225 shares during the period. Finally, Velan Capital Investment Management LP increased its stake in Heron Therapeutics by 25.3% during the third quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock worth $11,029,000 after acquiring an additional 1,766,546 shares during the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.